Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE (Details)

v3.22.1
SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]    
Total $ 39,251 $ 39,251
Accumulated Amortization (32,500) (31,964)
Net Carrying Value 6,751 7,287
CLIA Lab [Member]    
Restructuring Cost and Reserve [Line Items]    
Total $ 609 609
Finite lived intangible asset, useful life 2 years 3 months 18 days  
Asuragen Acquisition [Member] | Thyroid [Member]    
Restructuring Cost and Reserve [Line Items]    
Total $ 8,519 8,519
Finite lived intangible asset, useful life 9 years  
RedPath Acquisition [Member] | Pancreas Test [Member]    
Restructuring Cost and Reserve [Line Items]    
Total $ 16,141 16,141
Finite lived intangible asset, useful life 7 years  
RedPath Acquisition [Member] | Barrett's Test [Member]    
Restructuring Cost and Reserve [Line Items]    
Total $ 6,682 6,682
Finite lived intangible asset, useful life 9 years  
BioPharma Acquisition [Member] | Trademarks [Member]    
Restructuring Cost and Reserve [Line Items]    
Total $ 1,600 1,600
Finite lived intangible asset, useful life 10 years  
BioPharma Acquisition [Member] | Customer Relationships [Member]    
Restructuring Cost and Reserve [Line Items]    
Total $ 5,700 $ 5,700
Finite lived intangible asset, useful life 8 years